Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Translational Medicine
Published in: Journal of Translational Medicine 1/2015

Open Access 01-12-2015 | Review

Ebola: translational science considerations

Authors: Francesco Chiappelli, Andre Bakhordarian, April D Thames, Angela M Du, Allison L Jan, Melissa Nahcivan, Mia T Nguyen, Nateli Sama, Ercolano Manfrini, Francesco Piva, Rafael Malagoli Rocha, Carl A Maida

Published in: Journal of Translational Medicine | Issue 1/2015

Login to get access

Abstract

We are currently in the midst of the most aggressive and fulminating outbreak of Ebola-related disease, commonly referred to as “Ebola”, ever recorded. In less than a year, the Ebola virus (EBOV, Zaire ebolavirus species) has infected over 10,000 people, indiscriminately of gender or age, with a fatality rate of about 50%. Whereas at its onset this Ebola outbreak was limited to three countries in West Africa (Guinea, where it was first reported in late March 2014, Liberia, where it has been most rampant in its capital city, Monrovia and other metropolitan cities, and Sierra Leone), cases were later reported in Nigeria, Mali and Senegal, as well as in Western Europe (i.e., Madrid, Spain) and the US (i.e., Dallas, Texas; New York City) by late October 2014. World and US health agencies declared that the current Ebola virus disease (EVD) outbreak has a strong likelihood of growing exponentially across the world before an effective vaccine, treatment or cure can be developed, tested, validated and distributed widely. In the meantime, the spread of the disease may rapidly evolve from an epidemics to a full-blown pandemic. The scientific and healthcare communities actively research and define an emerging kaleidoscope of knowledge about critical translational research parameters, including the virology of EBOV, the molecular biomarkers of the pathological manifestations of EVD, putative central nervous system involvement in EVD, and the cellular immune surveillance to EBOV, patient-centered anthropological and societal parameters of EVD, as well as translational effectiveness about novel putative patient-targeted vaccine and pharmaceutical interventions, which hold strong promise, if not hope, to curb this and future Ebola outbreaks. This work reviews and discusses the principal known facts about EBOV and EVD, and certain among the most interesting ongoing or future avenues of research in the field, including vaccination programs for the wild animal vectors of the virus and the disease from global translational science perspective.
Literature
1.
Background reports: World Health Organization (WHO). Fact Sheet. Ebola virus disease. Fact sheet N°103. Updated September 2014; Centers for Disease Control and Prevention (CDC): Interim Guidance for Environmental Infection Control in Hospitals for Ebola Virus. October 3, 2014
2.
Bausch DG, Towner JS, Dowell SF, Kaducu F, Lukwiya M, Sanchez A, et al. Assessment of the risk of Ebola virus transmission from bodily fluids and fomites. J Infect Dis. 2007;196S:S142–7.
3.
WHO Ebola Response Team. Ebola Virus Disease in West Africa The First 9 Months of the Epidemic and Forward Projections. N Engl J Med. 2014 Epub: Sep 22. 2014
4.
Suzuki Y, Gojobori T. The origin and evolution of Ebola and Marburg viruses. Mol Biol Evol. 1997;14(8):800–6.PubMed
5.
Kuhn JH, Becker S, Ebihara H, Geisbert TW, Johnson KM, Kawaoka Y, et al. Proposal for a revised taxonomy of the family Filoviridae: Classification, names of taxa and viruses, and virus abbreviations. Arch Virol. 2010;155(12):2083–103.PubMedCentralPubMed
6.
Hoenen T, Groseth A, Falzarano D, Feldmann H. Ebola virus: unravelling pathogenesis to combat a deadly disease. Trends Mol Med. 2006;12(5):206–15.PubMed
7.
Gatherer D. The 2014 Ebola virus disease outbreak in West Africa. J Gen Virol. 2014;95(Pt 8):1619–24.PubMed
8.
9.
Wamala J, Lukwago L, Malimbo M, Nguku P, Yoti Z, Musenero M, et al. Ebola Hemorrhagic Fever Associated with Novel Virus Strain, Uganda, 2007–2008. Emerging Infectious Disease. 2010;16(7):21–9.
10.
Fisher-Hoch SP, Platt GS, Neild GH, Southee T, Baskerville A, Raymond RT, et al. Pathophysiology of shock and hemorrhage in a fulminating viral infection (Ebola). J Infect Dis. 1985;152(5):887–94.PubMed
11.
Weidmann M, Mühlberger E, Hufert FT. Rapid detection protocol for filoviruses. J Clin Virol. 2004;30(1):94–9.PubMed
12.
Formenty P, Leroy EM, Epelboin A, Libama F, Lenzi M, Sudeck H, et al. Detection of Ebola virus in oral fluid specimens during outbreaks of Ebola virus hemorrhagic fever in the Republic of Congo. Clin Infect Dis. 2006;42(11):1521–6.PubMed
13.
Garamszegi S, Yen JY, Honko AN, Geisbert JB, Rubins KH, Geisbert TW, et al. Transcriptional correlates of disease outcome in anticoagulant-treated non-human primates infected with ebolavirus. PLoS Negl Trop Dis. 2014;8(7):e3061. ePub: 2014 Jul.PubMedCentralPubMed
14.
Nakajima H, Watanabe N, Shibata F, Kitamura T, Ikeda Y, Handa M. N-terminal region of CCAAT/enhancer-binding protein epsilon is critical for cell cycle arrest, apoptosis, and functional maturation during myeloid differentiation. J Biol Chem. 2006;281(20):14494–502.PubMed
15.
Pulina MO, Sokolov AV, Zakharova ET, Kostevich VA, Vasilyev VB. Effect of lactoferrin on consequences of acute experimental hemorrhagic anemia in rats. Bull Exp Biol Med. 2010;149(2):219–22.PubMed
16.
Jangra RK, Yi M, Lemon SM. Regulation of hepatitis C virus translation and infectious virus production by the microRNA miR-122. J Virol. 2010;84(13):6615–25.PubMedCentralPubMed
17.
Bihrer V, Friedrich-Rust M, Kronenberger B, Forestier N, Haupenthal J, Shi Y, et al. Serum miR-122 as a biomarker of necroinflammation in patients with chronic hepatitis C virus infection. Am J Gastroenterol. 2001;106(9):1663–9.
18.
Janssen HL, Reesink HW, Lawitz EJ, Zeuzem S, Rodriguez-Torres M, Patel K, et al. Treatment of HCV infection by targeting microRNA. N Engl J Med. 2013;368(18):1685–94.PubMed
19.
Mitka M. Experimental RNA, therapy shows promise against Ebola virus in monkey studies. JAMA. 2010;304(1):31.PubMed
20.
21.
Garcia-Calvo M, Lisnock J, Bull HG, Hawes BE, Burnett DA, Braun MP, et al. The target of ezetimibe is Niemann-Pick C1-Like 1 (NPC1L1). Proc Natl Acad Sci U S A. 2005;102(23):8132–7.PubMedCentralPubMed
22.
Barrientos LG, O’Keefe BR, Bray M, Sanchez A, Gronenborn AM, Boyd MR. Cyanovirin-N binds to the viral surface glycoprotein, GP1,2 and inhibits infectivity of Ebola virus. Antiviral Res. 2003;58(1):47–56.PubMed
23.
Barkhordarian A, Hacker B, Chiappelli F. Dissemination of Evidence-Based Standards of Care. Bioinformation. 2011;7:315–9.PubMedCentralPubMed
24.
Barkhordarian A, Ramchandani MH, Dousti M, Kelly-Gleason L, Chiappelli F. Disseminating the Best Available Evidence: New Challenges in Public Reporting of Health Care. Bioinformation. 2012;8:293–5.PubMedCentralPubMed
25.
Chiappelli F, Barkhordarian A, Arora R, Phi L, Giroux A, Uyeda M, et al. Reliability of Quality Assessments in Research Synthesis: Securing the Highest Quality Bioinformation for HIT. Bioinformation. 2012;8:691–4.PubMedCentralPubMed
26.
Barkhordarian A, Pellionisz P, Dousti M, Lam V, Gleason L, Dousti M, et al. Assessment of risk of bias in translational science. J Transl Med. 2013;11:184–90.PubMedCentralPubMed
27.
Chiappelli F. Fundamentals of Evidence-based Health Care and Translational Science. Heidelberg: Springer–Verlag; 2014.
28.
Tambo E, Ugwu EC, Ngogang JY. Need of surveillance response systems to combat Ebola outbreaks and other emerging infectious diseases in African countries. Infect Dis Poverty. 2014 3:29. EPub Aug 5.
29.
Barrett R, Kuzawa CW, McDade T, Armelagos GJ. Emerging and re-emerging infectious diseases: The third epidemiologic transition. Annu Rev Anthropol. 1998;27:247–71.
30.
Armelagos GJ, Brown PJ, Turner B. Evolutionary, Historical and political economic perspectives on health and disease. Soc Sci Med. 2005;61:755–65.PubMed
31.
Muehlenbein MP. Human-wildlife contact and emerging infectious diseases. In: Brondízio ES, Moran EF, editors. Human-environment interactions: Current and future directions. Dordrecht: Springer; 2013. p. 79–94.
32.
Daszak P, Cunningham AA, Hyatt AD. Emerging infectious diseases of wildlife—Threats to biodiversity and human health. Science. 2000;287:443–9.PubMed
33.
Chapman CA, Gillespie TR, Goldberg TL. Primates and the ecology of their infectious diseases: How will anthropogenic change affect host-parasite interactions? Evolutionary Anthropology. 2005;14:134–44.
34.
Nading AM. Humans, animals, and health: From ecology to entanglement. Environment and Society: Advances in Research. 2013;4:60–78.
35.
Daszak P. Risky behavior in the Ebola zone. Anim Conserv. 2006;9:366–7.
36.
Brown H, Kelly AH. Material proximities and hotspots: Toward an anthropology of viral hemorrhagic fevers. Med Anthropol Q. 2014;28(2):280–303.PubMedCentralPubMed
37.
Hewlett BS, Amola RP. Cultural contexts of Ebola in Northern Uganda. Emerg Infect Dis. 2013;9(10):1242–8.
38.
Hewlett BS, Hewlett BL. Ebola, culture, and politics: The anthropology of an emerging disease. Thompson Wadsworth: Belmont, CA; 2008.
39.
Hewlett BS, Alain Epelboin A, Hewlett BL, Formenty P. Medical anthropology and Ebola in Congo: Cultural models and humanistic care. Bull Soc Pathol Exot. 2005;98:230–6.PubMed
40.
Hewlett BL, Hewlett BS. Providing care and facing death: Nursing during Ebola outbreaks in Central Africa. J Transcult Nurs. 2005;16(4):289–97.PubMed
41.
Bausch DG, Feldmann H, Geisbert TW, Bray M, Sprecher AG, Boumandouki O, et al. Outbreaks of filovirus hemorrhagic fever: Time to refocus on the patient. J Infect Dis. 2007;196:S136–41.PubMed
42.
Roddy P, Weatherill D, Jeffs B, Abaakouk Z, Dorion C, Rodriguez J, et al. The Médecins Sans Frontières intervention in the Marburg Hemorrhagic Fever epidemic, Uige, Angola 2005. II. Lessons learned in the community. J Infect Dis. 2007;207:162–7.
43.
Kinsman J. A time of fear”: local, national, and international responses to a large Ebola outbreak in Uganda. Glob Health. 2012;8(15):1–12.
44.
Calain P, Fiore N, Poncin M, Hurst SA. Research ethics and international epidemic response: The case of Ebola and Marburg hemorrhagic fevers. Public Health Ethics. 2009;2(1):7–29.
45.
Leach M, Barry S, Hewlettt BS. Haemorrhagic Fevers: Narratives, politics and pathways. In: Dry S, Leach M, editors. Epidemics: Science, governance and social justice. London: Earthscan; 2010. p. 43–69.
46.
Leach M, Scoones I. The social and political lives of zoonotic disease models: Narratives, science and policy. Soc Sci Med. 2013;88:10–7.PubMed
47.
48.
Brown PJ, Armelagos GR, Maes KC. Humans in a world of microbes: Anthropology of infectious disease. In: Singer M, Erickson PI, editors. A companion to medical anthropology. Malden, MA: Wiley-Blackwell; 2011. p. 253–70.
49.
Janes CR, Corbett KK, Jones JH, Trostle J. Emerging infectious diseases: The role of social sciences. Lancet. 2012;380:1884–6.PubMed
50.
Singer M, Clair S. Syndemics and public health: Reconceptualizing disease in bio-social context. Med Anthropol Q. 2003;17(4):423–41.PubMed
51.
Rock M, Buntain BJ, Hatfield JM, Hallgrimsson B. Animal-human connections, “one health, and the syndemic approach to prevention. Soc Sci Med. 2009;68:991–5.PubMed
52.
Lynteris C. The time of epidemics. Camb Anthropol. 2014;32(1):24–31.
53.
Raeymakers T. Reshaping the state in its margins: The state, the market and the subaltern on a Central African frontier. Crit Anthropol. 2012;32(3):334–50.
54.
Lakoff A. The generic biothreat, or, how we became unprepared. Cult Anthropol. 2008;23(3):399–428.
55.
Charles L, Briggs CL. Communicating biosecurity. Medical Anthropol. 2011;30(1):6–29.
56.
Caduff C. On the verge of death: visions of biological vulnerability. Annu Rev Anthropol. 2014;43(3):1–17.
57.
Harper I, Parker M. The politics and anti-politics of infectious disease control. Med Anthropol. 2014;33(3):198–205.PubMed
58.
Gonzalez JP, Pourrut X, Leroy E. Ebolavirus and other filoviruses. Current topics in microbiology and immunology. Curr Top Microbiol Immunol. 2007;315:363–87.PubMed
59.
Choi JH, Croyle MA. Emerging targets and novel approaches to Ebola virus prophylaxis and treatment. BioDrugs. 2013;27(6):565–83.PubMed
60.
61.
Ansari A. Clinical features and pathobiology of Ebolavirus infection. J Autoimmun. 2014;S0896:8411.
62.
Martinez O, Valmas C, Basler CF. Ebola virus-like particle-induced activation of NF-kappaB and Erk signaling in human dendritic cells requires the glycoprotein mucin domain. Virology. 2007;364:342–54.PubMedCentralPubMed
63.
64.
Wauquier N, Becquart P, Padilla C, Baize S, Leroy EM. Human fatal Zaire Ebola virus infection is associated with an aberrant innate immunity and with massive lymphocyte apoptosis. PLoS Negl TropDis. 2014;14:e837.
65.
Mahanty S, Hutchinson K, Agarwal S, Mcrae M, Rollin PE, Pulendre B. Cutting edge: impairment of dendritic cells and adaptive immunity by Ebola and Lassa viruses. J Immunol. 2003;170(6):2797–801.PubMed
66.
Nekludov M, Antovic J, Bredbacka S, Blombäck M. Coagulation abnormalities associated with severe isolated traumatic brain injury: cerebral arterio-venous differences in coagulation and inflammatory markers. J Neurotrauma. 2007;24(1):174–80.PubMed
67.
Berg LJ, Finkelstein LD, Lucas JA, Schwartzberg PL. Tec family kinases in T lymphocyte development and function. Annu Rev Immunol. 2005;23:549–600.PubMed
68.
Wilson CJ, Finch CE, Cohen H. Cytokines and cognition- The case for a head-to-toe inflammatory paradigm. J Am Geriatr Soc. 2002;50:2041–56.PubMed
69.
Sparkman NL, Buchanan JB, Heyen JR, Chen J, Beverly JL, Johnson RW. Interleukin-6 facilitates lipopolysaccharide-induced disruption in working memory and expression of other proinflammatory cytokines in hippocampal neuronal cell layers. J Neurosci. 2006;26:10709–16.PubMed
70.
Bauer S, Kerr BJ, Patterson PH. The neuropoietic cytokine family in development, plasticity, disease and injury. Nat Rev Neurosci. 2007;8:221–32.PubMed
71.
Erta M, Quintana A, Hidalgo J. Interleukin-6, a Major Cytokine in the Central Nervous System. Int J Biol Sci. 2012;8(9):1254–66.PubMedCentralPubMed
72.
Ekdahl CT, Claasen JH, Bonde S, Kokaia Z, Lindvall O. Inflammation is detrimental for neurogenesis in adult brain. Proc Natl Acad Sci U S A. 2003;100:13632–7.PubMedCentralPubMed
73.
Donegan JJ, Girotti M, Weinberg MS, Morilak DA. A novel role for brain interleukin-6: Facilitation of cognitive flexibility in rate orbitofrontal cortex. The Journal of Neuroscience. 2014;34(3):953–62.PubMedCentralPubMed
74.
Whitney NP, Eidem TM, Peng H, Huang Y, Zheng JC. Inflammation mediates varying effects in neurogenesis: relevance to the pathogenesis of brain injury and neurodegenerative disorders. J Neurochem. 2009;108:1343–59.PubMedCentralPubMed
75.
Baune T, Wiede F, Braun A, Golledge J, Arolt V, Koerner L. Cognitive dysfunction in mice deficient for TNF- and its receptor. Am J Med Genet B Neuropsychiatr Genet. 2008;147(7):1056–64.
76.
Beste C, Baune BT, Falkenstein M, Konrad C. Variations in the TNF-α gene (TNF-α -308G → A) affect attention and action selection mechanisms in a dissociated fashion. J Neurophysiol. 2010;104(5):2523–31.PubMed
77.
78.
Plata-Salamán CR. Cytokines and feeding. Int J Obes. 2001;25(s5):S48–52.
79.
Yao Y, Tsira SE. Monocyte chemoattractant protein-1 and the blood–brain barrier. Cell Mol Life Sci. 2014;71(4):683–97.PubMedCentralPubMed
80.
Hussain R, Ansari A, Talat N, Hasan Z, Dawood G. CCL2/MCP-1 Genotype-Phenotype in latent tuberculosis infection. PLoS One. 2011;6(10):e25803.PubMedCentralPubMed
81.
Uguccioni M, D’Apuzzo M, Loetscher M, Dewald B, Baggiolini M. Actions of the chemotactic cytokines MCP-1, MCP-2, MCP-3, RANTES, MIP-1 alpha and MIP-1 beta on human monocytes. Eur J Immunol. 1995;25:64–8.PubMed
82.
Conant K, Garzino-Demo A, Nath A, McArthur JC, Halliday W, Power C, et al. Induction of monocyte chemoattractant protein-1 in HIV-1 Tat-stimulated astrocytes and elevation in AIDS dementia. Proc Natl Acad Sci U S A. 1998;95(6):3117–21.PubMedCentralPubMed
83.
Eugenin EA, D’Aversa TG, Lopez L, Calderon TM, Berman JW. MCP-1 (CCL2) protects human neurons and astrocytes from NMDA or HIV-tat-induced apoptosis. J Neurochem. 2003;85:1299–311.PubMed
84.
Gonzalez E, Rovin BH, Sen L, Cooke G, Dhanda R, Mummidi S, et al. HIV-1 infection and AIDS dementia are influenced by a mutan MCP-1 allele linked to increased monocyte infiltration of tissues and MCP-1 levels. Proc Natl Acad Sci U S A. 2002;99:13795–800.PubMedCentralPubMed
85.
Kelder W, McArthur JC, Nance-Sproson T, McClernon D, Griffin DE. Beta-chemokines MCP-1 and RANTES are selectively increased in cerebrospinal fluid of patients with human immunodeficiency virus-associated dementia. Ann Neurol. 1998;44:831–5.PubMed
86.
Lehmann MH, Masanetz S, Kramer S, Erfle V. HIV-1 Nef upregulates CCL2/MCP-1 expression in astrocytes in a myristoylation- and calmodulin-dependent manner. J Cell Sci. 2006;119(21):4520–30.PubMed
87.
Letendre SL, Zheng JC, Kaul M, Yiannoutsos CT, Ellis RJ, Taylor MJ, et al. HIV Neuroimaging Consortium. Chemokines in cerebrospinal fluid correlate with cerebral metabolite patterns in HIV-infected individuals. J Neurovirol. 2011;17:63–9.PubMedCentralPubMed
88.
Galimberti D, Schoonenboom N, Scheltens P, Fenoglio C, Bouwman F, Venturelli E, et al. Intrathecal chemokine synthesis in mild cognitive impairment and Alzheimer disease. Arch Neurol. 2011;63(4):538–43.
89.
Aguzzi A, Barres BA, Bennett ML. Microglia: scapegoat, saboteur, or something else? Science. 2013;339(6116):156–61.PubMed
90.
91.
Abbott JN, Rönnbäck L, Hansson E. Astrocyte-endothelial interactions at the blood–brain barrier. Nat Rev Neurosci. 2006;7:41–53.PubMed
92.
Alcendor DJ, Charest AM, Zhu WQ, Vigil HE, Knobel SM. Infection and upregulation of proinflammatory cytokines in human brain vascular pericytes by human cytomegalovirus. J Neuroinflammation. 2012;9:95.PubMedCentralPubMed
93.
Stark K, Eckart A, Haidari S, Tirniceriu A, Lorenz M, von Bruhl ML, et al. Capillary and arteriolar pericytes attract innate leukocytes exiting through venules and ‘instruct’ them with pattern-recognition and motility programs. Nat Immunol. 2013;14:41–51.PubMed
94.
Davalos D, Ryu JK, Merlini M, Baeten KM, Le Moan N, Petersen MA, et al. Fibrinogen-induced perivascular microglial clustering is required for the development of axonal damage in neuroinflammation. Nat Commun. 2012;3:1227.PubMedCentralPubMed
95.
Abbott NJ. Inflammatory mediators and modulation of blood–brain barrier permeability. Cell Mol Neurobiol. 2000;20:131–47.PubMed
96.
Hawkins BT, Davis TP. The blood–brain barrier/neurovascular unit in health and disease. Pharmacol Rev. 2005;57(2):173–85.PubMed
97.
Hermann DM, Elai A. The abluminal endothelial membrane in neurovascular remodeling in health and disease. Sci Signal. 2012;5(236):re4.PubMed
98.
Wilson EH, Weninger W, Hunter CA. Trafficking of immune cells in the central nervous system. J Clin Invest. 2010;120:1368–79.PubMedCentralPubMed
99.
Pardridge M. Blood–brain barrier drug targeting: the future of brain drug development. Mol Interv. 2003;3:90–105.PubMed
100.
Wahl-Jensen VM, Afanasieva TA, Seebach J, Stroher U, Feldmann H, Schnittler HJ. Effects of Ebola virus glycoproteins on endothelial cell activation. American Society for Microbiology. 2005;16:10042–450.
101.
Mu H, Chai H, Lin PH, Yao Q, Chen C. Current update on HIV-associated vascular disease and endothelial dysfunction. World J Surg. 2007;31(4):632–43.PubMed
102.
Toborek M, Lee Y, Flora G, Pu H. Mechanisms of the blood–brain barrier disruption in HIV-1 infection. Cell Mol Neurobiol. 2005;25(1):181–99.PubMed
103.
Minagar A, Alexander JS. Blood–brain barrier disruption in multiple sclerosis. Mult Scler. 2003;9:540–9.PubMed
104.
Murphy FA. Pathology of Ebola virus infection. In: Pattyn SR, editor. Ebolavirus haemorrhagic fever. Amsterdam: Elsevier/North-Holland Biomedical Press; 1978. p. 43–60.
105.
Whitley RJ, Gnann JW. Viral encephalitis. Lancet. 2002;359:507–14.PubMed
106.
Kauder SE, Racaniello VR. Poliovirus tropism and attenuation are determined after internal ribosome entry. J Clin Invest. 2004;113(12):1743–53.PubMedCentralPubMed
107.
Takada A. Filovirus tropism: cellular molecules for viral entry. Front Microbiol. 2012;6(3):34.
108.
Papadopoulos MC, Manley GT, Krishna S, Verkman AS. Aquaporin-4 facilitates reabsorption of excess fluid in vasogenic brain edema. FASEB J. 2004;18:1291–3.PubMed
109.
Kaufman DM. Lumbar puncture and imaging. In D. Kaufman. Clinical Neurology for Psychiatrists. Sauders New York; 2006
110.
Kreiter KT, Copeland D, Bernardini GL, Bates JE, Peery S, Claassen J, et al. Predictors of cognitive dysfunction after subarachnoid hemorrhage. Stroke. 2002;33:200–9.PubMed
111.
Wong G, Kobinger GP, Qiu X. Characterization of host immune responses in Ebola virus infections. Expert Rev Clin Immunol. 2014;10(6):7819.
112.
Ramanan P, Shabman RS, Brown CS, Amarasinghe GK, Basler CF, Leung DW. Filoviral immune evasion mechanisms. Viruses. 2011;3(9):163449.
113.
Leung DW, Prins KC, Basler CF, Amarasinghe GK. Ebolavirus VP35 is a multifunctional virulence factor. Virulence. 2010;1:526–31.PubMedCentralPubMed
114.
Warfield KL, Olinger G, Deal EM, Swenson DL, Bailey M, Negley DL, et al. Induction of humoral and CD8+ T cell responses are required for protection against lethal Ebola virus infection. J Immunol. 2005;175(2):1184–91.PubMed
115.
Zampieri CA, Sullivan NJ, Nabel GJ. Immunopathology of highly virulent pathogens: insights from Ebola virus. Nat Immunol. 2007;8(11):1159–64.PubMed
116.
Rogers NM, Ferenbach DA, Isenberg JS, Thomson AW, Hughes J. Dendritic cells and macrophages in the kidney: a spectrum of good and evil. Nature Reviews Nephrology. 2014. Epub 30 September
117.
Assas BM, Miyan JA, Pennock JL. Cross-talk between neural and immune receptors provides a potential mechanism of homeostatic regulation in the gut mucosa. Mucosal Immunol. 2014;7:1283–9.PubMed
118.
Tacchetti C, Favre A, Moresco L, Meszaros P, Luzzi P, Truini M, et al. HIV is trapped and masked in the cytoplasm of lymph node follicular dendritic cells. Am J Pathol. 1997;150(2):533–42.PubMedCentralPubMed
119.
Gill PS, Arora DR, Arora B, Gill M, Gautam V, Karan J, et al. Lymphadenopathy an important guiding tool for detecting hidden HIV-positive cases: a 6-year study. J Int Assoc Physicians AIDS Care (Chic). 2007;6(4):269–72.
120.
Bradfute SB, Warfield KL, Bavari S. Functional CD8+ T cell responses in lethal Ebola virus infection. J Immunol. 2008;180(6):4058–66.PubMed
121.
Bradfute SB, Swanson PE, Smith MA, Watanabe E, McDunn JE, Hotchkiss RS, et al. Mechanisms and consequences of ebolavirus-induced lymphocyte apoptosis. J Immunol. 2010;184(1):327–35.PubMed
122.
Han L, Liu F, Li R, Li Z, Chen X, Zhou Z, et al. Role of programmed death ligands in effective T-cell interactions in extranodal natural killer/T-cell lymphoma. Oncol Lett. 2014;8(4):1461–9.PubMedCentralPubMed
123.
Bour-Jordan H, Bluestone JA. Regulating the regulators: costimulatory signals control the homeostasis and function of regulatory T cells. Immunol Rev. 2009;229(1):41–66.PubMedCentralPubMed
124.
Bour-Jordan H, Esensten JH, Martinez-Llordella M, Penaranda C, Stumpf M, Bluestone JA. Intrinsic and extrinsic control of peripheral T-cell tolerance by costimulatory molecules of the CD28/ B7 family. Immunol Rev. 2011;241(1):180–205.PubMedCentralPubMed
125.
Kow NY, Mak A. Costimulatory pathways: physiology and potential therapeutic manipulation in systemic lupus erythematosus. Clin Dev Immunol. 2013; 245928. ePub July.
126.
Leroy EM, Baize S, Lu CY, McCormick JB, Georges AJ, Georges-Courbot MC, et al. Diagnosis of Ebola haemorrhagic fever by RT-PCR in an epidemic setting. J Med Virol. 2000;60(4):463–7.PubMed
127.
Bray M, Geisbert TW. Ebola virus: the role of macrophages and dendritic cells in the pathogenesis of Ebola hemorrhagic fever. Int J Biochem Cell Biol. 2005;37:1560–6.PubMed
128.
Military Health System, US. Ebola Fact Sheet for Families of Deploying Personnel Fact. Sheet 10/17/2014.
129.
Pandjassarame K, Sakharkar MK, Flower DR, Sadler K, Chiappelli F, Segal DM, et al. Designing HIV Gp120 Peptide Vaccines: Rhetoric or Reality For NeuroAids. Chapter 9. In: Goodkin K, Shapshak P, Verma A, editors. The Spectrum of Neuro-AIDS Disorders: Pathophysiology, Diagnosis, and Treatment. Washington, DC: ASM Press; 2008.
130.
Meltzer MI, Atkins CY, Santibanez S, Knust B, Petersen BW, Ervin ED, et al. Estimating the future number of cases in the ebola epidemic Liberia and Sierra Leone, 20142015. MMWR Surveill Summ. 2014;26(63):1114.
131.
Nyamathi AM, Fahey JL, Sands H, Casillas AM. Ebola virus: immune mechanisms of protection and vaccine development. Biol Res Nurs. 2003;4(4):276–88.PubMed
132.
Wilson JA, Bosio CM, Hart MK. Ebola virus: the search for vaccines and treatments. Cell Mol Life Sci. 2001;58(1213):1826–41.PubMed
133.
Gire SK, Goba A, Andersen KG, Sealfon RS, Park DJ, Kanneh L, et al. Genomic surveillance elucidates Ebola virus origin and transmission during the 2014 outbreak. Science. 2014;345(6202):1369–72.PubMed
134.
Editorial. Ebola vaccine trials raise ethical issues. Science. 2014;346:289–90.
135.
Gehring G, Rohrmann K, Atenchong N, Mittler E, Becker S, Dahlmann F, et al. The clinically approved drugs amiodarone, dronedarone and verapamil inhibit filovirus cell entry. J Antimicrob Chemother. 2014;69(8):2123–31.PubMed
136.
McCarthy M. US signs contract with ZMapp maker to accelerate development of the Ebola drug. BMJ. 2014;349:g5488.PubMed
137.
Qiu X, Wong G, Audet J, Bello A, Fernando L, Alimonti JB, et al. Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp. Nature. 2014;514(7520):47–53.PubMed
138.
Pettitt J, Zeitlin L, Kim Do H, Working C, Johnson JC, Bohorov O, et al. Therapeutic intervention of Ebola virus infection in rhesus macaques with the MB-003 monoclonal antibody cocktail. Sci Transl Med. 2013;5(199):199ra113.PubMed
139.
Jerne NK. Towards a network theory of the immune system. Ann Immunol. 1974;125C:373–89.
140.
Jäger A, Kuchroo VK. Effector and Regulatory T-cell Subsets in Autoimmunity and Tissue Inflammation. Scand J Immunol. 2010;72:173–84.PubMedCentralPubMed
141.
Komatsu N, Okamoto K, Sawa S, Nakashima T, Oh-hora M, Kodama T, et al. Pathogenic conversion of Foxp3+ T cells into TH17 cells in autoimmune arthritis. Nat Med. 2014;20:62–8.PubMed
142.
143.
Qu N, Xu M, Mizoguchi I, Furusawa J, Kaneko K, Watanabe K, et al. Pivotal Roles of T-Helper 17-Related Cytokines, IL-17, IL-22, and IL-23, in Inflammatory Diseases. Clin Dev Immunol. 2013; 968549. Epub July 13.
144.
145.
Gupta M, Mahanty S, Ahmed R, Rollin PE. Monocyte-derived human macrophages and peripheral blood mononuclear cells infected with ebola virus secrete MIP-1alpha and TNF-alpha and inhibit poly-IC-induced IFN-alpha in vitro. Virology. 2001;284(1):20–5.PubMed
146.
Leroy EM, Baize S, Volchkov VE, Fisher-Hoch SP, Georges-Courbot MC, Lansoud-Soukate J, et al. Human asymptomatic Ebola infection and in a complex and interactive model of care strong inflammatory response. Lancet. 2000;355(9222):2210–5.PubMed
147.
Dzik JM. The ancestry and cumulative evolution of immune reactions. Acta Biochemica Polonica. 2010;57:443–66.
148.
Cooper EL. Evolution of immune systems from self/not self to danger to artificial immune systems (AIS). Physics of Life Reviews. 2010;7:55–78.PubMed
149.
Janeway CA. The immune system evolved to dis- criminate infectious nonself from noninfectious self. Immunol Today. 1992;13:11–6.PubMed
150.
Beutler BA. TLRs and innate immunity. Blood. 2009;113:399–407.
151.
Kawai T, Akira S. Toll-like receptors and their crosstalk with other innate receptors in infection and immunity. Immunity. 2011;34:637–50.PubMed
152.
Morris SM. Arginine metabolism: boundaries of our knowledge. J Nutr. 2007;137(1):602–9.
153.
Morris SM. Recent advances in arginine metabolism: roles and regulation of the arginases. Brit Jour Pharmacol. 2009;157:922–30.
154.
Hibbs JB, Vavrin Z, Taintor RR. L-arginine is required for expression of the activated macro- phage effector mechanism causing selective metabolic inhibition in target cells. J Immunol. 1987;138:550–65.PubMed
155.
Hibbs JB, Taintor RR, Vavrin Z. Macrophage cytotoxicity: role for L-arginine deiminase and imino nitrogen oxidation to nitrite. Science. 1987;235:473–6.PubMed
156.
157.
Mills CD. M1 and M2 Macrophages: Oracles of Health and Disease. Crit Rev Immunol. 2012;32:463–88.PubMed
158.
Marinez FO, Gordon S. The M1 and M2 paradigm of macrophage activation: time for reassessment. F1000Prime Reports. 2014; 6:13. Ecollection March
159.
MacMicking J, Xie QW, Nathan C. Nitric oxide and macrophage function. Annu Rev Immunol. 1997;15:323–50.PubMed
160.
Mills CD. Macrophage arginine metabolism to ornithine/urea or nitric oxide/citrulline: A life or death issue. Crit Rev Immunol. 2001;21:399–425.PubMed
161.
Nathan CF, Hibbs JB. Role of nitric oxide synthesis in macrophage antimicrobial activity. Curr Opin Immunol. 1991;3:65–70.PubMed
162.
McCall TB, Boughton-Smith NK, Palmer RM, Whittle BJ, Moncada S. Synthesis of nitric oxide from L-arginine by neutrophils. Release and interaction with superoxide anion. Biochem J. 1989;261:293–6.PubMedCentralPubMed
163.
Bermudez LE. Production of transforming growth factor-beta by Mycobacterium avium-infected human macrophages is associated with unresponsiveness to IFN-gamma. J Immunol. 1993;150:1838–45.PubMed
164.
Hsieh CS, Macatonia SE, Tripp CS, Wolf SF, O’Garra A, Murphy KM. Development of TH1 CD4+ T cells through IL-12 produced by Listeria- induced macrophages. Science. 1993;260:547–9.PubMed
165.
Williams-Ashman HG, Canellakis ZN. Polyamines in mammalia biology and medicine. Perspect Biol Med. 1979;22:421–53.PubMed
166.
Macatonia SE, Hosken NA, Litton M, Vieira P, Hsieh CS, Culpepper JA, et al. Dendritic cells produce IL-12 and direct the development of Th1 cells from naive CD4+ T cells. J Immunol. 1995;154:5071–9.PubMed
167.
168.
Stuehr DJ, Marletta MA. Induction of nitrite/nitrate synthesis in murine macrophages by BCG infection, lymphokines, or interferon-gamma. J Immunol. 1987;139:518–25.PubMed
169.
Ding A, Nathan CF, Graycar J, Derynck R, Stuehr DJ, Srimal S. Macrophage deactivating factor and transforming growth factors-beta 1 -beta 2 and -beta 3 inhibit induction of macrophage nitrogen oxide synthesis by IFN-gamma. J Immunol. 1990;145:940–4.PubMed
170.
Rosenthal AS, Shevach EM. Function of macrophages in antigen recognition by guinea pig T lymphocytes. I. Requirement for histocompatible macrophages and lymphocytes. J Exp Med. 1973;138:194–212.
171.
Ding AH, Nathan CF, Stuehr DJ. Release of reactive nitrogen intermediates and reactive oxygen intermediates from mouse peritoneal macrophages. Comparison of activating cytokines and evidence for independent production. J Immunol. 1988;141:2407–12.PubMed
172.
Scharton-Kersten T, Afonso LC, Wysocka M, Trinchieri G, Scott P. IL-12 is required for natural killer cell activation and subsequent T helper 1 cell development in experimental leishmaniasis. J Immunol. 1995;154:5320–30.PubMed
173.
Alleva DG, Kaser SB, Beller DI. Intrinsic defects in macrophage IL-12 production associated with immune dysfunction in the MRL/++ and New Zealand Black/White F1 lupus-prone mice and the Leishmania major-susceptible BALB/c strain. J Immunol. 1998;161:6878–84.PubMed
174.
Li J, Hunter CA, Farrell JP. Anti-TGF-beta treatment promotes rapid healing of Leishmania major infection in mice by enhancing in vivo nitric oxide production. J Immunol. 1999;162:974–9.PubMed
175.
Roberts AB, Sporn MB, Assoian RK, Smith JM, Roche NS, Wakefield LM, et al. Transforming growth factor type beta, rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro. Proc Natl Acad Sci U S A. 1986;83:4167–71.PubMedCentralPubMed
176.
Assoian RK, Fleurdelys BE, Stevenson HC, Miller PJ, Madtes DK, Raines EW, et al. Expression and secretion of type beta transforming growth factor by activated human macrophages. Proc Natl Acad Sci U S A. 1987;84:6020–4.PubMedCentralPubMed
177.
Stevens RB, Sutherland DE, Ansite JD, Saxena M, Rossini TJ, Levay-Young BK, et al. Insulin down-regulates the inducible nitric oxide synthase pathway, nitric oxide as cause and effect of diabetes? J Immunol. 1997;159:5329–35.PubMed
178.
Toossi Z, Hirsch CS, Hamilton BD, Knuth CK, Friedlander MA, Rich EA. Decreased production of TGF-beta 1 by human alveolar macrophages compared with blood monocytes. J Immunol. 1996;156:3461–8.PubMed
179.
Boutard V, Havouis R, Fouqueray B, Philippe C, Moulinoux JP, Baud L. Transforming growth factor-beta stimulates arginase activity in macrophages. Implications for the regulation of macrophage cytotoxicity. J Immunol. 1995;155:2077–84.PubMed
180.
Shearer JD, Richards JR, Mills CD, Caldwell MD. Differential regulation of macrophage arginine, metabolism, a proposed role in wound healing. Am J Physiol. 1997;272:E181–90.PubMed
181.
Mills CD, Kincaid K, Alt JA, Heilman MJ, Hill AH. M-1/M-2 macrophages and the Th1/Th2 paradigm. J Immunol. 2000;164:6166–73.PubMed
182.
Tsunawaki S, Sporn M, Ding A, Nathan C. Deactivation of macrophages by transforming growth factor-beta. Nature (London). 1988;334:260–2.
183.
Rutschman R, Lang R, Hesse M, Ihle JN, Wynn TA, Murray PJ. Cutting edge, Stat6-dependent substrate depletion regulates nitric oxide production. J Immunol. 2001;166:2173–7.PubMed
184.
Corraliza IM, Soler G, Eichmann K, Modolell M. Arginase induction by suppressors of nitric oxide synthesis (IL-4, IL- 10 and PGE2) in murine bone- marrow-derived macrophages. Biochem Biophys Res Commun. 1995;206:667–73.PubMed
185.
Puddu P, Fantuzzi L, Borghi P, Varano B, Rainaldi G, Guillemard E, et al. IL-12 induces IFN- gamma expression and secretion in mouse peritoneal macrophages. J Immunol. 1997;159(7):3490–7.PubMed
186.
Lawrence T, Natoli G. Transcriptional regulation of macrophage polarization: enabling diversity with identity. Nat Rev Immunol. 2011;11:750–61.PubMed
187.
Cassetta L, Cassol E, Poli G. Macrophage Polarization in Health and Disease. SciWorld Journ. 2011;11(2):391–402.
188.
Gabrilovich DI, Ostrand-Rosenberg S, Bronte V. Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol. 2012;12:253–68.PubMedCentralPubMed
189.
Munder M, Mallo M, Eichmann K, Modolell M. Murine macrophages secrete interferon gamma upon combined stimulation with interleukin (IL)-12 and IL-18: a novel pathway of autocrine macrophage activation. J Exp Med. 1998;187(12):2103–8.PubMedCentralPubMed
190.
Romo N, Magri G, Muntasell A, Heredia G, Baía D, Angulo A, et al. Natural killer cell-mediated response to human cytomegalovirus-infected macrophages is modulated by their functional polarization. J Leuk Biol. 2011;90:717–26.
191.
192.
Anthony RM, Urban Jr JF, Alem F, Hamed HA, Rozo CT, Boucher JL. Memory TH2 cells induce alternatively activated macrophages to mediate protection against nematode parasites. Nat Med. 2006;12:955–6.PubMedCentralPubMed
193.
Modolell M, Corraliza IM, Link F, Soler G, Eichmann K. Reciprocal regulation of the nitric oxide synthase/arginase balance in mouse bone marrow-derived macrophages by TH1 and TH2. cytokines. Eur J Immunol. 1995;25:1,101.
194.
DeNardo DG, Brennan DJ, Rexhepaj E, Ruffell B, Shiao SL, Madden SF, et al. Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov. 2011;1(1):54–67.PubMedCentralPubMed
195.
Ries CH, Cannarile MA, Hoves S, Benz J, Wartha K, Runza V, et al. Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy. Cancer Cell. 2014;25(6):846–59.PubMed
196.
Taetzsch T, Levesque S, McGraw C, Brookins S, Luqa R, Bonini MG, et al. Redox regulation of NF-κB p50 and M1 polarization in microglia. Glia. 2014. Epub: Oct 21.
197.
Porta C, Rimoldi M, Raes G, Brys L, Ghezzi P, Di Liberto D, et al. Tolerance and M2 (alternative) macrophage polarization are related processes orchestrated by p50 nuclear factor kappaB. Proc Natl Acad Sci U S A. 2009;106(35):14978–83.PubMedCentralPubMed
198.
Geisbert TW, Young HA, Jahrling PB, Davis KJ, Kagan E, Hensley LE. Mechanisms underlying coagulation abnormalities in ebola hemorrhagic fever: overexpression of tissue factor in primate monocytes/macrophages is a key event. J Infect Dis. 2003;188(11):1618–29.PubMed
199.
Ferguson LR, Karunasinghe N, Zhu S, Wang AH. Selenium and its’ role in the maintenance of genomic stability. Mutat Res. 2012;733(1–2):100–10.PubMed
200.
Shetty SP, Shah R, Copeland PR. Regulation of selenocysteine incorporation into the selenium transport protein, selenoprotein P. J Biol Chem. 2014;289(36):25317–26.PubMed
201.
Ramanathan CS, Taylor EW. Computational genomic analysis of hemorrhagic fever viruses. Viral selenoproteins as a potential factor in pathogenesis. Biol Trace Elem Res. 1997;56(1):93–106.PubMed
202.
Liang H, Zhou Z, Zhang S, Zen K, Chen X, Zhang C. Identification of Ebola virus microRNAs and their putative pathological function. Sci China Life Sci. 2014;57(10):973–81.PubMed
203.
Sheng M, Zhong Y, Chen Y, Du J, Ju X, Zhao C, et al. Hsa-miR-1246, hsa-miR-320a and hsa-miR-196b-5p inhibitors can reduce the cytotoxicity of Ebola virus glycoprotein in vitro. Sci China Life Sci. 2014;57(10):959–72.PubMed
204.
Deverka PA, Lavallee DC, Desai PJ, Esmail LC, Ramsey SD, Veenstra DL, et al. Stakeholder participation in comparative effectiveness research: defining a framework for effective engagement. J Comp Eff Res. 2012;1:181–94.PubMedCentralPubMed
205.
Aarons GA, Wells RS, Zagursky K, Fettes DL, Palinkas LA. Implementing Evidence-Based Practice in Community Mental Health Agencies: A Multiple Stakeholder Analysis. Am J Public Health. 2009;99:2087–95.PubMedCentralPubMed
206.
de Almeida MJ, Carvalho Costa B, de Faria RM D, Figueiredo Soares T, Perlatto Moura E, Chiappelli F. Improving communication skill training in patient centered medical practice for enhancing rational use of laboratory tests: The core of bioinformation for leveraging stakeholder engagement in regulatory science. Bioinformation. 2013;9:718–20.
207.
Moncrief JW. Telemedicine: the slow revolution. Adv Perit Dial. 2014;30:125–7.PubMed
208.
Preston J, Brown FW, Hartley B. Using telemedicine to improve health care in distant areas. Hosp Community Psychiatry. 1992;43(1):25–32.PubMed
209.
Bediang G, Perrin C, de Ruiz Castañeda R, Kamga Y, Sawadogo A, Bagayoko CO, et al. The RAFT Telemedicine Network: Lessons Learnt and Perspectives from a Decade of Educational and Clinical Services in Low- and Middle-Incomes Countries. Front Public Health. 2014;2:180.PubMedCentralPubMed
210.
Giles-Vernick T, Rupp S. People, great apes, disease, and global health in the northern forests of Equatorial Africa. In: Giles-Vernick T, Webb Jr LA, editors. Global health in Africa: Historical perspectives on disease control. Athens Ohio: Ohio University Press; 2013. p. 117–37.
211.
Rupprecht CE, Hanlon CA, Slate D. Oral vaccination of wildlife against rabies: opportunities and challenges in prevention and control. Dev Biol. 2004;119:173–84.
212.
Almeida MF, Martorelli LF, Aires CC, Barros RF, Massad E. Vaccinating the vampire bat Desmodus rotundus against rabies. Virus Res. 2008;137(2):275–7.PubMed
213.
Anderson A, Shwiff S, Gebhardt K, Ramírez AJ, Shwiff S, Kohler D, et al. Economic evaluation of vampire bat (Desmodus rotundus) rabies prevention in Mexico. Transbound Emerg Dis. 2014;61(2):140–6.PubMed
214.
Maganga GD, Bourgarel M, Vallo P, Dallo TD, Ngoagouni C, Drexler JF, et al. Bat distribution size or shape as determinant of viral richness in african bats. PLoS One. 2014;9(6):e100172. Epub June 24.PubMedCentralPubMed
Metadata
Title
Ebola: translational science considerations
Authors
Francesco Chiappelli
Andre Bakhordarian
April D Thames
Angela M Du
Allison L Jan
Melissa Nahcivan
Mia T Nguyen
Nateli Sama
Ercolano Manfrini
Francesco Piva
Rafael Malagoli Rocha
Carl A Maida
Publication date
01-12-2015
Publisher
BioMed Central
Published in
Journal of Translational Medicine / Issue 1/2015
Electronic ISSN: 1479-5876
DOI
https://doi.org/10.1186/s12967-014-0362-3

Other articles of this Issue 1/2015

Journal of Translational Medicine 1/2015 Go to the issue

Research

Assessment of the effector function of CMV-specific CTLs isolated using MHC-multimers from granulocyte-colony stimulating factor mobilized peripheral blood

Research

Relationship between ITPA polymorphisms and hemolytic anemia in HCV-infected patients after ribavirin-based therapy: a meta-analysis

Review

Fighting against kidney diseases with small interfering RNA: opportunities and challenges

Research

The clearance effect of bovine anti-Helicobacter pylori antibody-containing milk in O blood group Helicobacter pylori-infected patients: a randomized double-blind clinical trial

Research

Identification of potential biomarkers to differentially diagnose solid pseudopapillary tumors and pancreatic malignancies via a gene regulatory network

Research

Anti-dsDNA antibodies induce inflammation via endoplasmic reticulum stress in human mesangial cells
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits